NUCB1 and neoplasm: Although it has been demonstrated that NUCB1 overexpression helps tumor progression [96], a 5-year follow-up study showed the worst prognosis for pancreatic ductal adenocarcinoma (PDAC) patients with low levels of NUCB1.